Reflection and ReactionCholine kinase alpha in cancer prognosis and treatment
References (9)
- et al.
Structure and function of choline kinase isoforms in mammalian cells
Prog Lipid Res
(2004) - et al.
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study
Lancet Oncol
(2007) - et al.
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers
Biochem Biophys Res Commun
(2002) - et al.
Alterations of choline phospholipid metabolism in ovarian tumor progression
Cancer Res
(2005)
Cited by (43)
Fine Needle Aspiration Combined With Matrix-assisted Laser Desorption Ionization Time-of-Flight/Mass Spectrometry to Characterize Lipid Biomarkers for Diagnosing Accuracy of Breast Cancer
2017, Clinical Breast CancerCitation Excerpt :The use of MALDI-TOF/MS to characterize breast cancer biomarkers in FNA specimens will be helpful in improving the accuracy of breast cancer diagnoses. Certain lipids have been reported as potential breast cancer biomarkers,16-32 with some studies focusing on the composition and turnover of lipids in breast cancer tissues. For example, the results of 2-dimensional thin layer chromatography indicated that the contents of phospholipids such as phosphatidylcholines (PCs) tended to be 4-fold higher, and triacylglycerol (TG) levels are 65% lower in human breast cancer tissues when compared with their normal tissue counterparts.17
Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry
2014, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesEnhanced choline metabolism in a rodent rhabdomyosarcoma model: Correlation between RT-PCR and translational 3 T H-MRS
2012, Magnetic Resonance ImagingCitation Excerpt :A potential concern could be raised regarding field strength, since the tCho peak at 3T includes not only “native” choline (substrate of kinases) but also downstream metabolites such as PC (product of kinases), GPC and betaine [33]. Nevertheless, it has been demonstrated that PC is by far the major component of the tCho peak at 3T [33,34], and that decreases in the tCho peak and in PC levels as measured by 31P-MRS were strongly paralleled in human breast MDA-MB-231 cancer cells under treatment [35]. We therefore consider the tCho peak to adequately reflect the level of activity of the Kennedy cycle even without an indicator of the activity of the potentially ‘output-limiting’ CCT enzyme.
Synthesis of oncological [ <sup>11</sup>C]radiopharmaceuticals for clinical PET
2012, Nuclear Medicine and BiologyCitation Excerpt :In the biosynthesis of this phospholipid, choline is phosphorylated by choline kinase to phosphorylcholine which is converted to phosphatidylcholine. Several malignant tumors have been shown to overexpress choline kinase [31], resulting in increased levels of phosphorylcholine by accumulation of free choline for cell membrane synthesis [32–34]. For this reason, [11C]choline was introduced as a radiopharmaceutical for oncological PET studies of a variety of malignant diseases [35–38].
A concise review of mass spectrometry imaging
2010, Journal of Chromatography A